The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19
Visualitza/Obre
Autor/a
Borralleras, Cristina
Castrodeza Sanz, Javier
Cámara Hijón, Carmen
Eiros, José Mª
Fernández-Prada, María
Gil de Miguel, Ángel
Mirada Masip, Gloria
Moraga-Llop, Fernando
Ocaña Rodríguez, Daniel
Puig-Barberà, Joan
Vázquez, Jorge
Vergara-Alert, Júlia
de Cambra, Salomé
Data de publicació
2023-06-12ISSN
0214-3429
Resum
Objectives. Vaccination against SARS-CoV-2 is essential
to mitigate the personal, social and global impact of the coronavirus disease (COVID-19) as we move from a pandemic to
an endemic phase. Vaccines are now required that offer broad,
long-lasting immunological protection from infection in addition to protection from severe illness and hospitalisation. Here
we present a review of the evidence base for a new COVID-19
vaccine, PHH-1V (Bimervax®; HIPRA HUMAN HEALTH S.L.U),
and the results of an expert consensus.
Materials and methods. The expert committee consisted
of Spanish experts in medicine, family medicine, paediatrics,
immunology, microbiology, nursing, and veterinary medicine.
Consensus was achieved using a 4-phase process consisting of
a face-to-face meeting during which the scientific evidence
base was reviewed, an online questionnaire to elicit opinions
on the value of PHH-1V, a second face-to-face update meeting to discuss the evolution of the epidemiological situation,
vaccine programmes and the scientific evidence for PHH-1V
and a final face-to-face meeting at which consensus was
achieved.
Results. The experts agreed that PHH-1V constitutes a
valuable novel vaccine for the development of vaccination
programmes aimed towards protecting the population from
SARS-CoV-2 infection and disease. Consensus was based on evidence of broad-spectrum efficacy against established and
emerging SARS-CoV-2 variants, a potent immunological response, and a good safety profile. The physicochemical properties of the PHH-1V formulation facilitate handling and storage
appropriate for global uptake.
Conclusions- The physicochemical properties, formulation, immunogenicity and low reactogenic profile of PHH-1V
confirm the appropriateness of this new COVID-19 vaccine.
Tipus de document
Article
Versió del document
Versió publicada
Llengua
Anglès
Matèries (CDU)
619 - Veterinària
Pàgines
9
Publicat per
Sociedad Española de Quimioterapia
Publicat a
Revista Española de Quimioterapia
Citació
Borralleras, Cristina, José Antonio Sanz, Pilar Arrazola, Carmen Cámara Hijón, José María Eiros, María Fernández-Prada, Ángel Gil De Miguel, et al. 2023. “The PHH-1V HIPRA Vaccine: A New Tool in the Vaccination Strategy against COVID-19.” Revista Española de Quimioterapia. 36 (5): 507–515. doi:10.37201/req/046.2023.
Programa
Sanitat Animal
Aquest element apareix en la col·lecció o col·leccions següent(s)
- ARTICLES CIENTÍFICS [2639]
Els següents fitxers sobre la llicència estan associats a aquest element:
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by-nc/4.0/